Abstract：
UNASSIGNED: Delirium is a neuropsychiatric condition that commonly occurs in medical settings, especially among older individuals. Despite the lack of strong evidence in the literature, haloperidol is considered the first-line pharmacological intervention. Unfortunately, its adverse effects can be severe, and psychiatrists are considering the use of alternative drugs targeting dopamine and serotonin domains (atypical antipsychotics). Among them, aripiprazole is considered to have one of the safest pharmacological profiles.
UNASSIGNED: The purpose of this study is to examine the studies on aripiprazole as a pharmacological treatment of delirium present in today\'s literature.
UNASSIGNED: We carried out systematic research of MedLine, PubMed, Cochrane, Embase, and ScienceDirect examining articles written between January 2002 and September 2023, including experimental studies published in peer-reviewed journals.
UNASSIGNED: The 6 final included studies examined a total of 130 patients, showing a delirium resolution in a 7-day span of 73.8% of patients treated with aripiprazole.
UNASSIGNED: Considering the limited data currently available, we can assert that aripiprazole is at least as efficient as haloperidol, the true point is that it has a far better tolerability and safety profile. Nonetheless, further studies are necessary to provide more compelling data, together with a more precise indication regarding minimum efficient dose, as the main limitations of our review are the very small sample size, the small percentage of subjects with preexisting dementia, and the fact that most studies used scales with low specificity for the examined condition.
UNASSIGNED: The purpose of this study is to examine the studies on aripiprazole as a pharmacological treatment of delirium present in today\'s literature.
UNASSIGNED: We carried out systematic research of MedLine, PubMed, Cochrane, Embase, and ScienceDirect examining articles written between January 2002 and September 2023, including experimental studies published in peer-reviewed journals.
UNASSIGNED: The 6 final included studies examined a total of 130 patients, showing a delirium resolution in a 7-day span of 73.8% of patients treated with aripiprazole.
UNASSIGNED: Considering the limited data currently available, we can assert that aripiprazole is at least as efficient as haloperidol, the true point is that it has a far better tolerability and safety profile. Nonetheless, further studies are necessary to provide more compelling data, together with a more precise indication regarding minimum efficient dose, as the main limitations of our review are the very small sample size, the small percentage of subjects with preexisting dementia, and the fact that most studies used scales with low specificity for the examined condition.
摘要：
■谵妄是一种在医疗环境中常见的神经精神疾病，尤其是老年人。尽管文献中缺乏强有力的证据,氟哌啶醇被认为是一线药物干预。不幸的是,它的副作用可能很严重，精神科医生正在考虑使用针对多巴胺和5-羟色胺结构域的替代药物（非典型抗精神病药）。其中,阿立哌唑被认为是最安全的药理作用之一。
■本研究的目的是考察目前文献中关于阿立哌唑作为谵妄药物治疗的研究。
■我们对MedLine进行了系统的研究，PubMed,科克伦,Embase,和ScienceDirect审查2002年1月至2023年9月之间撰写的文章，包括发表在同行评审期刊上的实验研究。
■6项最终纳入研究共检查了130名患者，在接受阿立哌唑治疗的患者中，73.8%的患者出现谵妄消退。
■考虑到当前可用的有限数据，我们可以断言阿立哌唑至少和氟哌啶醇一样有效，真正的观点是它具有更好的耐受性和安全性。尽管如此，需要进一步的研究来提供更有说服力的数据，以及关于最低有效剂量的更精确的指示，由于我们审查的主要限制是样本量非常小，一小部分先前存在痴呆症的受试者，以及大多数研究使用对所检查条件具有低特异性的量表的事实。
■本研究的目的是考察目前文献中关于阿立哌唑作为谵妄药物治疗的研究。
■我们对MedLine进行了系统的研究，PubMed,科克伦,Embase,和ScienceDirect审查2002年1月至2023年9月之间撰写的文章，包括发表在同行评审期刊上的实验研究。
■6项最终纳入研究共检查了130名患者，在接受阿立哌唑治疗的患者中，73.8%的患者出现谵妄消退。
■考虑到当前可用的有限数据，我们可以断言阿立哌唑至少和氟哌啶醇一样有效，真正的观点是它具有更好的耐受性和安全性。尽管如此，需要进一步的研究来提供更有说服力的数据，以及关于最低有效剂量的更精确的指示，由于我们审查的主要限制是样本量非常小，一小部分先前存在痴呆症的受试者，以及大多数研究使用对所检查条件具有低特异性的量表的事实。
